Comparative Pharmacology
Head-to-head clinical analysis: CECLOR CD versus CEFOTAXIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CECLOR CD versus CEFOTAXIME.
CECLOR CD vs CEFOTAXIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
Cefotaxime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
250-500 mg orally every 8 hours; extended-release form (CECLOR CD) 375-750 mg orally every 12 hours.
1-2 g IV every 6-8 hours; maximum 12 g/day. For uncomplicated infections: 1 g IV every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life: ~0.6-0.9 hours (prolonged in renal impairment)
Clinical Note
moderateCefotaxime + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefotaxime."
Clinical Note
moderateCefotaxime + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefotaxime."
Clinical Note
moderateWarfarin + Cefotaxime
"Warfarin may increase the anticoagulant activities of Cefotaxime."
Clinical Note
moderatePhenprocoumon + Cefotaxime
Terminal elimination half-life: 1-1.5 hours in adults with normal renal function. In neonates, it is prolonged to 2-4 hours. In severe renal impairment (CrCl <20 mL/min), half-life extends up to 10-15 hours, requiring dose adjustment.
Renal: ~80% unchanged; biliary/fecal: ~20%
Approximately 80-90% of the dose is excreted unchanged in the urine via glomerular filtration and tubular secretion. About 5-10% is excreted in bile and feces as desacetylcefotaxime, the active metabolite.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Cefotaxime."